Table 3.
Clinical characteristics of the patients of the BRCC cohort. RC, rectal cancer; AJCC, American Joint Committee on Cancer; Categorical data reported as n (%). Continuous data reported as median (IQR)
| Mucinous RC (N = 15) | Non-Mucinous RC (N = 43) | p-value | ||
|---|---|---|---|---|
| Male | 53.3% (8) | 58.1% (25) | 0.75 | |
| Age | Median (IQR) | 71 (29–81) | 70(42–89) | 0.10 |
| Stage | AJCC 1 | 13.3% (2) | 11.6% (5) | 0.17 |
| AJCC 2 | 60.0% (9) | 34.8% (15) | ||
| AJCC 3 | 26.0% (4) | 53.4%(23) | ||
| AJCC4 | 0.0% (0) | 0.0%(0) | ||
| T stage | Tis-T1-T-2 | 20.0% (3) | 25.5% (11) | 0.28 |
| T3 | 60.0% (9) | 65.1% (28) | ||
| T4 | 20.0% (3) | 9.3% (4) | ||
| N stage | N0 | 73.3% (11) | 48.8% (21) | 0.52 |
| N1 | 6.7% (1) | 41.8%(18) | ||
| N2 | 20.0% (3) | 9.3%(4) | ||
| M stage | M0 | 100% (15) | 100% (43) | NA |
| M1 | 0.0% (0) | 0.0% (0) | ||
| Neoadjuvant CRT(n = 56)a | 53.3% (8) | 69.8% (30) | 0.32 | |
| Adjuvant CRT (n = 52)a | 53.3% (8) | 39.5% (17) | 0.26 | |
| MSI (n = 55)a | 14.3%(2) | 2.4% (1) | 0.09 | |
| KRAS (n = 55)a | Mutant | 35.7%(5) | 17.1%(7) | 0.15 |
| BRAF (n = 54)a | Mutant | 7.7%(1) | 2.4% (1) | 0.38 |
| LVI (n = 57)a | 6.7%(1) | 19%(8) | 0.26 | |
| Perineural invasion (n = 56)a | 14.3%(2) | 11.9%(5) | 0.82 | |
| Extramural invasion (n = 56)a | 7.1%(1) | 19.0%(8) | 0.29 |
aData not available in full cohort: n in parentheses = number with data available